Johns hopkins medicine initiates patient enrollment for renovorx's ongoing phase iii tiger-pac clinical trial

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing innovative targeted oncology therapies and commercializing renovocath®, a novel, fda-cleared drug-delivery device, today announced that johns hopkins medicine is now initiated to enroll patients with locally advanced pancreatic cancer (lapc) in renovorx's ongoing phase iii tiger-pac clinical trial. johns hopkins medicine becomes the newest addition to a disting.
RNXT Ratings Summary
RNXT Quant Ranking